Journal of Veterinary Science

The Korean Society of Veterinary Science (대한수의학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of FMD virus-like particles in yeast Hansenula polymorpha and immunogenicity of combine with CpG and aluminum adjuvant

  • Jianhui Zhang (College of Veterinary Medicine, Gansu Agricultural University) ;
  • Jun Ge (Grand Theravac Life Sciences (Nanjing) Co., Ltd.) ;
  • Juyin Li (Jiangsu Argi-animal Husbandry Vocational College) ;
  • Jianqiang Li (Grand Theravac Life Sciences (Nanjing) Co., Ltd.) ;
  • Yong Zhang (College of Veterinary Medicine, Gansu Agricultural University) ;
  • Yinghui Shi (Grand Theravac Life Sciences (Nanjing) Co., Ltd.) ;
  • Jiaojiao Sun (Grand Theravac Life Sciences (Nanjing) Co., Ltd.) ;
  • Qiongjin Wang (Grand Theravac Life Sciences (Nanjing) Co., Ltd.) ;
  • Xiaobo Zhang (Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University) ;
  • Xingxu Zhao (College of Veterinary Medicine, Gansu Agricultural University)
  • Received : 2022.09.19
  • Accepted : 2022.12.12
  • Published : 2023.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Inactivated vaccines are limited in preventing foot-and-mouth disease (FMD) due to safety problems. Recombinant virus-like particles (VLPs) are an excellent candidate for a novel vaccine for preventing FMD, given that VLPs have similar immunogenicity as natural viruses and are replication- and infection-incompetent. Objectives: The 3C protease and P1 polyprotein of type O FMD virus (FDMV) was expressed in yeast Hansenula polymorpha to generate self-resembling VLPs, and the potential of recombinant VLPs as an FMD vaccine was evaluated. Methods: BALB/c mice were immunized with recombinant purified VLPs using CpG oligodeoxynucleotide and aluminum hydroxide gel as an adjuvant. Cytokines and lymphocytes from serum and spleen were analyzed by enzyme-linked immunosorbent assay, enzyme-linked immunospot assay, and flow cytometry. Results: The VLPs of FMD were purified successfully from yeast protein with a diameter of approximately 25 nm. The immunization of mice showed that animals produced high levels of FMDV antibodies and a higher level of antibodies for a longer time. In addition, higher levels of interferon-γ and CD4+ T cells were observed in mice immunized with VLPs. Conclusions: The expression of VLPs of FMD in H. polymorpha provides a novel strategy for the generation of the FMDV vaccine.

Keywords

Acknowledgement

The authors would like to thank Ph.D. Keshan Zhang of Lanzhou Veterinary Research Institute for his helpfulness in this study.

References

  1. Abrams CC, King AM, Belsham GJ. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol. 1995;76(Pt 12):3089-3098. https://doi.org/10.1099/0022-1317-76-12-3089
  2. Jamal SM, Belsham GJ. Foot-and-mouth disease: past, present and future. Vet Res. 2013;44(1):116.
  3. Mahapatra M, Parida S. Foot and mouth disease vaccine strain selection: current approaches and future perspectives. Expert Rev Vaccines. 2018;17(7):577-591. https://doi.org/10.1080/14760584.2018.1492378
  4. Gao Y, Sun SQ, Guo HC. Biological function of foot-and-mouth disease virus non-structural proteins and non-coding elements. Virol J. 2016;13(1):107.
  5. Robinson L, Knight-Jones TJ, Charleston B, Rodriguez LL, Gay CG, Sumption KJ, et al. Global foot-and-mouth disease research update and gap analysis: 3 - vaccines. Transbound Emerg Dis. 2016;63 Suppl 1:30-41. https://doi.org/10.1111/tbed.12521
  6. Rodriguez LL, Gay CG. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Rev Vaccines. 2011;10(3):377-387. https://doi.org/10.1586/erv.11.4
  7. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31(1):58-83. https://doi.org/10.1016/j.vaccine.2012.10.083
  8. Mignaqui AC, Ruiz V, Durocher Y, Wigdorovitz A. Advances in novel vaccines for foot and mouth disease: focus on recombinant empty capsids. Crit Rev Biotechnol. 2019;39(3):306-320. https://doi.org/10.1080/07388551.2018.1554619
  9. Xie Y, Li H, Qi X, Ma Y, Yang B, Zhang S, et al. Immunogenicity and protective efficacy of a novel foot-and-mouth disease virus empty-capsid-like particle with improved acid stability. Vaccine. 2019;37(14):2016-2025. https://doi.org/10.1016/j.vaccine.2019.02.032
  10. Xiao Y, Zhang S, Yan H, Geng X, Wang Y, Xu X, et al. The high immunity induced by the virus-like particles of foot-and-mouth disease virus serotype O. Front Vet Sci. 2021;8:633706.
  11. Guo HC, Sun SQ, Jin Y, Yang SL, Wei YQ, Sun DH, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res. 2013;44(1):48.
  12. Baghban R, Farajnia S, Rajabibazl M, Ghasemi Y, Mafi A, Hoseinpoor R, et al. Yeast expression systems: overview and recent advances. Mol Biotechnol. 2019;61(5):365-384. https://doi.org/10.1007/s12033-019-00164-8
  13. Stockmann C, Scheidle M, Dittrich B, Merckelbach A, Hehmann G, Melmer G, et al. Process development in Hansenula polymorpha and Arxula adeninivorans, a re-assessment. Microb Cell Fact. 2009;8(1):22.
  14. Manfrao-Netto JH, Gomes AM, Parachin NS. Advances in using Hansenula polymorpha as chassis for recombinant protein production. Front Bioeng Biotechnol. 2019;7:94.
  15. Guzman E, Taylor G, Charleston B, Skinner MA, Ellis SA. An MHC-restricted CD8+ T-cell response is induced in cattle by foot-and-mouth disease virus (FMDV) infection and also following vaccination with inactivated FMDV. J Gen Virol. 2008;89(Pt 3):667-675. https://doi.org/10.1099/vir.0.83417-0
  16. Kayraklioglu N, Horuluoglu B, Klinman DM. CpG oligonucleotides as vaccine adjuvants. Methods Mol Biol. 2021;2197:51-85. https://doi.org/10.1007/978-1-0716-0872-2_4
  17. Reed SG, Tomai M, Gale MJ Jr. New horizons in adjuvants for vaccine development. Curr Opin Immunol. 2020;65:97-101. https://doi.org/10.1016/j.coi.2020.08.008
  18. Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138(5):779-795.
  19. Near KA, Stowers AW, Jankovic D, Kaslow DC. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect Immun. 2002;70(2):692-701. https://doi.org/10.1128/iai.70.2.692-701.2002
  20. Hemmi T, Ainai A, Hashiguchi T, Tobiume M, Kanno T, Iwata-Yoshikawa N, et al. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. Vaccine. 2022;40(41):5892-5903. https://doi.org/10.1016/j.vaccine.2022.08.049
  21. Singh RK, Sharma GK, Mahajan S, Dhama K, Basagoudanavar SH, Hosamani M, et al. Foot-and-mouth disease virus: immunobiology, advances in vaccines and vaccination strategies addressing vaccine failures-an Indian perspective. Vaccines (Basel). 2019;7(3):90.
  22. Terhuja M, Saravanan P, Tamilselvan RP. Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I:C or CpG in guinea pigs. Biologicals. 2015;43(6):437-443. https://doi.org/10.1016/j.biologicals.2015.09.004
  23. Alves MP, Guzylack-Piriou L, Juillard V, Audonnet JC, Doel T, Dawson H, et al. Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs. Clin Vaccine Immunol. 2009;16(8):1151-1157. https://doi.org/10.1128/CVI.00018-09
  24. Cao Y. Adjuvants for foot-and-mouth disease virus vaccines: recent progress. Expert Rev Vaccines. 2014;13(11):1377-1385. https://doi.org/10.1586/14760584.2014.963562
  25. Li H, Yang Y, Zhang Y, Zhang S, Zhao Q, Zhu Y, et al. A hydrophobic interaction chromatography strategy for purification of inactivated foot-and-mouth disease virus. Protein Expr Purif. 2015;113:23-29. https://doi.org/10.1016/j.pep.2015.04.011